曲美他嗪治疗冠心病心力衰竭临床评价

目的评价曲美他嗪治疗冠心病心力衰竭的临床疗效及安全性。方法选择114例冠心病心力衰竭患者随机分为治疗组50例和对照组64例。对照组给予常规抗心力衰竭治疗；治疗组在对照组常规治疗基础上加服曲美他嗪20mg，3次／d。2组疗程均为6个月。观察两组治疗前后临床疗效、左室舒张末内径（LVEDD）、左室射血分数（LVEF）、血清B型尿钠肽（BNP）、6min步行试验及药物不良反应等。结果治疗6个月后，治疗组的总有效率显著高于对照组（P〈0．05）；在LVEDd、LVEF、6min步行距离及BNP等方面改善的程度，治疗组均优于对照组（P〈0．05）；治疗组发生药物不良反应少而轻微。结论冠心病心力衰竭患者长期服用曲美他嗪可使心功能改善．安伞有效。

Clinical evaluation of trimetazidine in patients with coronary heart disease and chronic heart failure

Objective To evaluate the clinical therapeutic effects and safety of trimetazidine(TMZ) in patients with coronary heart disease(CHD)and chronic heart failure(CHF). Methods 114 patients with CHD and CHF were randomly divided into treatment group 50 cases and the control group 64 cases. The control group was given conventional anti-heart failure therapy; The treatment group were given 20 mg trimetazidine (3 times per day) on the basis of conventional therapy of the control group. The course of treatment all were 6 months in 2Groups. Clinical efficacy, left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF) ,serum B-type natriuretic peptide(BNP) ,6 min walk test,and adverse drug reactions were observed before and 6 months after therapy. Results After treatment for 6 months, the total effective rate of the treatment group was significantly higher than that of the control group( P ＜ 0.05 ); The LVEDd, LVEF, 6-minute walking distance and the level of BNP in the treatment group improved significantly better than that of the control group ( P ＜ 0.05 ); the treatment group occurred few and mild adverse drug reactions. Conclusion Long-term use trimetazidine treating in patients with with CHD and CHF can improve cardiac function, safe and effective.